• Cancel
    Date：2025-08

    Exclusive Financial Advisor to BridgeDP

  • Cancel
    Date：2025-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=904

    On the evening of June 30, 2025, Suning.com (002024) announced that its first interim shareholders' meeting of 2025 had approved the Proposal on the Sale of Subsidiary Equity by Suning International Holding’s Subsidiary Carrefour China Holdings N.V. CEC Capital acted as the exclusive financial advisor to Suning.com for this transaction.

  • Cancel
    Date：2025-04

    Exclusive Financial Advisor to IREGENE

  • Cancel
    Date：2025-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=873

    Recently, Geneus Technologies, a leading domestic company in nanopore sequencing technology, announced the completion of a nearly RMB 100 million B++ round of financing. This round of funding was led by CDBT Group, with participation from Si Chuan Venture

  • Cancel
    Date：2025-02

    Exclusive Financial Advisor to QL Biopharm

  • Cancel
    Date：2024-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=865

    Recently, BridgeDP, an emerging startup in the embodied intelligence sector, announced it has raised several tens of millions of RMB in its angel financing. The round was co-led by Zhengxuan Investment and Fosun Capital. CEC Capital acted as the exclu

  • Cancel
    Date：2024-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=860

    Xiaoyu Bot, the first robotics company in the Xiaomi ecosystem to leverage large model technology, recently announced the closing of its Series A financing, raising 100 million RMB. The round was exclusively funded by the Beijing Information Industry Deve

  • Cancel
    Date：2024-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=854

    Recently, Dingzhi Dental, a leading brand and expert in complex dental implants in China, announced the closing of its Series A financing, raising several hundred million RMB, with Eight Roads as the sole investor. CEC Capital served as the exclusive

  • Cancel
    Date：2024-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=848

    Wuhan-based iRegene, which aims to become a global leader in universal chemically induced cell therapy, recently announced the closing of its Series B financing, raising several hundred million RMB. The round was co-led by Orinno Capital and CDBT Group, w